What is the clinically relevant endpoint for cancer prevention trials? Maurie Markman Editor’s Commentary Pages: 329 - 330
Novel approaches to immunotherapy for B-cell malignancies Renier J. Brentjens OriginalPaper Pages: 339 - 347
Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia Clive S. ZentNeil E. Kay OriginalPaper Pages: 348 - 354
New molecular targets for treatment of lymphoma Barbara ProAnas Younes OriginalPaper Pages: 360 - 368
The genetics of familial lymphomas Rina SiddiquiKenan OnelKenneth Offit OriginalPaper Pages: 380 - 387
Primary central nervous system lymphoma Igor T. GavrilovicLauren E. Abrey OriginalPaper Pages: 388 - 395
Overview of melanoma vaccines and promising approaches Monica C. PanelliEna WangFrancesco M. Marincola OriginalPaper Pages: 414 - 420